Angiotensin (1-7)

Catalog No.S9820 Batch:S982001

Print

Technical Data

Formula

C41H62N12O11

Molecular Weight 899.00 CAS No. 51833-78-4
Solubility (25°C)* In vitro Water 50 mg/mL (55.61 mM)
DMSO Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Angiotensin (1-7) (Ang-(1-7), Angiotensin fragment 1-7) is a bioactive component of the renin-angiotensin system that is formed endogenously from either Ang I or Ang II. Angiotensin (1-7) is a canine ACE inhibitor with an IC50 of 0.65 μM and inhibits the activity mediated by myostatin through Mas receptor.
Targets
Mas receptor [1] ACE [1]
0.65 μM
In vitro

Angiotensin (1-7) prevents the decrease of the myotube diameter and MHC Levels Induced by myostatin in C2C12 cells. Angiotensin (1-7) decreases the myostatin-dependent increment of E3 ubiquitin ligases and ROS, the NF-κB signaling induced by myostatin, the myostatin-dependent activity through the mas receptor and Akt/PKB activity in C2C12 myotubes.[1]

In vivo

Daily Angiotensin (1-7) administration significantly reduces colitis severity observable at both gross and histological levels in DSS treated mice. The anti-inflammatory effects of Angiotensin (1-7) treatment are associated with a reduction in the phosphorylated forms of p38 MAPK, ERK1/2 and Akt post DSS induction, the anti-inflammatory properties of Angiotensin (1-7) are in part mediated through reduction of Ang II levels.[3]

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    C2C12 cells

  • Concentrations

    10 nM

  • Incubation Time

    30 min, 60 min

  • Method

    The C2C12 cells are differentiated until day 5 by changing DMEM–FSB to DMEM supplemented with horse serum. The myotubes are incubated with 1 µg/ml of human recombinant myostatin and/or 10 nM of Angiotensin (1-7). The myotubes are treated with 10 µM of MK2206 for Akt/PKB inhibition, or 10 µM of A779 antagonist for Mas receptor inhibition. In brief, the procedure is as follows: differentiated cells are pre-treated with Angiotensin (1-7) for 30 or 60 min, depending on the experiments, and then treated with myostatin.

Animal Study:

[3]

  • Animal Models

    DSS treated mice

  • Dosages

    0.01 mg/kg, 0.06 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg

  • Administration

    i.p.

Selleck's Angiotensin (1-7) has been cited by 1 publication

ACE2 negatively regulates the Warburg effect and suppresses hepatocellular carcinoma progression via reducing ROS-HIF1α activity [ Int J Biol Sci, 2023, 19(8):2613-2629] PubMed: 37215979

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.